Ultime notizie per Vontier (NYSE:VNT) Azioni

Vontier

Vontier, spun off from Fortive in 2020, is an industrial technology company with a portfolio of transportation and mobility solutions. The company offers a wide array of products and services, including fueling equipment, sensors, point-of-sale and payment systems, telematics, and equipment used by vehicle mechanics and technicians. Vontier generated approximately $3 billion in sales in 2024.

Vontier Corp

VENTANA GLOBAL INC by Ventana Global Inc.

Ventana Global Inc

VINTE VIVNDAS INTEGRALE by VINTE VIVIENDAS INTEGRALES S A B

Vinte Viviendas Integrales SAPI de CV

NANO MOBILE HEALTHCARE by Nano Mobile Healthcare, Inc.

Nano Mobile Healthcare Inc

VENTURENET CAP GROUP INC by VentureNet Capital Group, Inc.

VentureNet Capital Group Inc

Venator Materials PLC

VENATOR MATERIALS PLC by Venator Materials PLC

Toast, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) released its first-quarter results after Thursday's closing bell. Here's a look at the details <a href="https://www.benzinga.com/pressreleases/25/05/b45299394/toast-announces-first-quarter-2025-financial-results">in the report. </a>
The Details: Toast reported quarterly earnings of nine cents per share, which missed the Street estimate of 12 cents. Quarterly revenue came in at $1.34 billion, in line with the consensus estimate.
The company <a href="https://www.benzinga.com/pressreleases/25/05/b45299714/toast-tees-up-new-technology-platform-for-topgolf">also announced</a> an agreement with Topgolf to implement Toast Enterprise Solutions across its venues in the U.S.
Read Next: <a href="https://www.benzinga.com/news/earnings/25/05/45292652/thursdays-top-5-trending-stocks-whats-going-on-with-d-wave-novavax-carvana?utm_source=articleShare">Thursday&#8217;s Top 5 Trending Stocks: What&#8217;s Going On With D-Wave, Novavax, Carvana?</a>
For the first quarter, Toast reported: 
<ul>
<li>ARR as of March 31, 2025, was $1.7 billion, up 31% year-over-year.</li>
<li>Total Locations increased 25% year-over-year to approximately 140,000.</li>
<li>Gross Payment Volume (GPV) increased 22% year-over-year to $42.2 billion.</li>
<li>Non-GAAP subscription services and financial technology solutions gross profit grew 37% year-over-year to $415 million.</li>
</ul>
&#8220;Toast kicked off the year with a fantastic first quarter — we added over 6,000 net new locations, grew our recurring gross profit streams 37%, and delivered $133 million in Adjusted EBITDA,&#8221; said Toast CEO Aman Narang.
&#8220;We continue to see strong momentum across both our core business as well as our new verticals in international, retail, and enterprise including marquee wins in Applebee&#8217;s and Topgolf. We are starting to see our scale and data across our 140,000 locations help our customers be more successful, which sets us up well as we continue to build out the platform and scale globally,&#8221; Narang added. 
TOST Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Toast stock was up 8.43% at $39.74 after-hours Thursday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/travel/25/05/45260938/disneys-new-abu-dhabi-theme-park-will-be-authentically-disney-and-distinctly-emirati-ceo-bob-iger-says?utm_source=articleShare">Disney&#8217;s New Abu Dhabi Theme Park Will Be &#8216;Authentically Disney And Distinctly Emirati,&#8217; CEO Bob Iger Says&nbsp;</a></li>
</ul>
Photo: Shutterstock

Earnings

News

Restaurants

After-Hours Center

Movers

Tech

TOST

Toast Stock Rallies After Q1 Results, Signs Agreement With Topgolf

J.P. Morgan analyst Bill Peterson reiterated an Overweight rating on the shares of Evgo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) with a price forecast of $5.00.
EVgo <a target="_blank" href="https://www.benzinga.com/25/05/45233228/whats-going-on-with-evgo-stock-today" rel="noreferrer noopener">beat revenue expectations</a>, thanks in part to stronger-than-anticipated performance from its eXtend business, said the analyst.
The company reaffirmed both its financial and stall deployment targets, easing investor concerns around the stability of its Department of Energy (DOE) loan, which saw a second drawdown in April and remains on track for quarterly disbursements over five years.
Management believes EVgo is well-positioned to grow market share in fast charging, especially as peers face challenges from uncertain EV policies and reduced spending by site hosts.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45236630/ford-outperforms-in-q1-faces-tariff-challenges-ahead-say-analysts" rel="noreferrer noopener">Ford Outperforms In Q1, Faces Tariff Challenges Ahead, Say Analysts</a>
The analyst stated that additional non-dilutive funding and potential small-scale acquisitions may further support growth.
Tariff-related cost impacts are expected to be manageable at around $4–5 million in 2025, with much of the affected equipment already in inventory or en route. The company anticipates that cost-saving measures will help absorb these expenses.
EVgo operates one of the largest DC fast-charging networks in the U.S., generating revenue from its expanding charger base.
The company adds capacity based on growing demand and offers a reliable network that is compatible with all EVs, including Teslas, without adapters.
With strong partnerships across automakers, rideshare, and autonomous fleets, EVgo is well-positioned for robust revenue growth, driven by rising utilization, faster charging, and potential DOE loan support, concluded the analyst.
Price Action: EVGO shares closed higher by 4.36% at $3.83 on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/45299775" target="_blank" rel="noreferrer noopener">Tesla Tried To Trademark &#8216;Robotaxi&#8217; And &#8216;Cybercab&#8217; Terms: Why It Could Be Forced To Pick A New Name</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Price Target

Reiteration

Analyst Ratings

Trading Ideas

General

EVGO

TSLA

EVgo Is Well-Positioned For Robust Revenue Growth: Analyst

ECN Capital (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ECN#TSX">ECN</a>) reported quarterly earnings of $0.03 per share. The company reported $56.63 million in sales this quarter. This is a 14.16 percent increase over sales of $49.61 million the same period last year.

TSX:ECN

ECN Capital Q1 Adj. EPS $0.03, Sales $56.63M Up From $49.61M YoY

Alliant Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>) affirms FY2025 Adj EPS guidance from $3.15-$3.25 to $3.15-$3.25 vs $3.21 analyst estimate..

Guidance

Alliant Energy Affirms FY2025 Adj EPS Guidance of $3.15-$3.25 vs $3.21 Est

Alliant Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNT#NASDAQ">LNT</a>) reported quarterly earnings of $0.83 per share which beat the analyst consensus estimate of $0.66 by 25.76 percent. This is a 33.87 percent increase over earnings of $0.62 per share from the same period last year. The company reported quarterly sales of $1.13 billion which beat the analyst consensus estimate of $985.38 million by 14.47 percent. This is a 9.41 percent increase over sales of $1.03 billion the same period last year.

Earnings Beats

Alliant Energy Q1 Adj. EPS $0.83 Beats $0.66 Estimate, Sales $1.13B Beat $985.38M Estimate

Alaris Equity Partners (TSX:<a class="ticker" href="https://www.benzinga.com/stock/AD#TSX">AD</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.40 by 25 percent. This is a 67.11 percent decrease over earnings of $1.52 per share from the same period last year. The company reported quarterly sales of $36.39 million which missed the analyst consensus estimate of $43.82 million by 16.96 percent. This is a 23.28 percent decrease over sales of $47.43 million the same period last year.

Earnings Misses

TSX:AD

Alaris Equity Partners Q1 EPS $0.50 Beats $0.40 Estimate, Sales $36.39M Miss $43.82M Estimate

Atlanticus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATLC#NASDAQ">ATLC</a>) reported quarterly earnings of $1.49 per share which beat the analyst consensus estimate of $1.48 by 0.68 percent. This is a 36.7 percent increase over earnings of $1.09 per share from the same period last year. The company reported quarterly sales of $344.87 million which missed the analyst consensus estimate of $347.24 million by 0.68 percent. This is a 18.63 percent increase over sales of $290.71 million the same period last year.

ATLC

Atlanticus Holdings Q1 EPS $1.49 Beats $1.48 Estimate, Sales $344.87M Miss $347.24M Estimate

Turnstone Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSBX#NASDAQ">TSBX</a>) reported quarterly losses of $(0.51) per share which missed the analyst consensus estimate of $(0.26) by 96.15 percent. This is a 40 percent increase over losses of $(0.85) per share from the same period last year.

TSBX

Turnstone Biologics Q1 EPS $(0.51) Misses $(0.26) Estimate

Doman Building Materials (TSX:<a class="ticker" href="https://www.benzinga.com/stock/DBM#TSX">DBM</a>) reported quarterly earnings of $0.27 per share which beat the analyst consensus estimate of $0.12 by 125 percent. This is a 68.75 percent increase over earnings of $0.16 per share from the same period last year. The company reported quarterly sales of $793.20 million which beat the analyst consensus estimate of $757.38 million by 4.73 percent. This is a 31.66 percent increase over sales of $602.48 million the same period last year.

TSX:DBM

Doman Building Materials Q1 Adj. EPS $0.27 Beats $0.12 Estimate, Sales $793.20M Beat $757.38M Estimate

NNBR

CORRECTION: NN Lowers FY2025 Sales Guidance To $430.00M-$460.00M vs $454.30M Est

Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) affirms FY2025 Adj EPS guidance from $6.64-$7.28 to $6.64-$7.28 vs $6.97 analyst estimate. Affirms FY2025 sales outlook from $1.44 billion-$1.50 billion to $1.44 billion-$1.50 billion vs $1.46 billion estimate.

Ziff Davis Affirms FY2025 Adj EPS Guidance of $6.64-$7.28 vs $6.97 Est; Affirms FY2025 Sales Guidance of $1.44B-$1.50B vs $1.46B Est

Karat Packaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>) affirms FY2025 sales outlook from $460.67 million-$469.12 million to $460.67 million-$469.12 million vs $461.42 million estimate.

Karat Packaging Reiterating FY2025 guidance on net sales, gross margin and adjusted EBITDA margin.

Ziff Davis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZD#NASDAQ">ZD</a>) reported quarterly earnings of $1.14 per share which missed the analyst consensus estimate of $1.25 by 8.8 percent. This is a 10.24 percent decrease over earnings of $1.27 per share from the same period last year. The company reported quarterly sales of $328.64 million which beat the analyst consensus estimate of $324.19 million by 1.37 percent. This is a 4.50 percent increase over sales of $314.49 million the same period last year.

Ziff Davis Q1 Adj. EPS $1.14 Misses $1.25 Estimate, Sales $328.64M Beat $324.19M Estimate

Canacol Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CNE#TSX">CNE</a>) reported quarterly earnings of $0.93 per share. This is a 745.45 percent increase over earnings of $0.11 per share from the same period last year. The company reported $72.73 million in sales this quarter. This is a 6.38 percent decrease over sales of $77.69 million the same period last year.

TSX:CNE

Canacol Energy Q1 EPS $0.93 Up From $0.11 YoY, Sales $72.73M Down From $77.69M YoY

Across the recent three months, 4 analysts have shared their insights on Generation Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GBIO#NASDAQ">GBIO</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $8.25, with a high estimate of $9.00 and a low estimate of $8.00. Holding firm without variation, the current average remains at the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2025/1746741664_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The analysis of recent analyst actions sheds light on the perception of Generation Bio by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Generation Bio. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Generation Bio compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Generation Bio's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Generation Bio's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GBIO/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Generation Bio analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Generation Bio</h2>
Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
<h3>Unraveling the Financial Story of Generation Bio</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Generation Bio's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 45.52% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Generation Bio's net margin excels beyond industry benchmarks, reaching -510.55%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Generation Bio's ROE excels beyond industry benchmarks, reaching -22.43%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Generation Bio's ROA excels beyond industry benchmarks, reaching -8.91%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 1.09, Generation Bio adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Basics of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GBIO

Where Generation Bio Stands With Analysts

10 analysts have expressed a variety of opinions on MarketAxess Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKTX#NASDAQ">MKTX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for MarketAxess Holdings, presenting an average target of $235.7, a high estimate of $295.00, and a low estimate of $191.00. Observing a 0.08% increase, the current average has risen from the previous average price target of $235.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1746741652_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of MarketAxess Holdings's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Allen</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$265.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$240.00</td>
<td>$232.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$202.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Kyle Voigt</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$226.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$283.00</td>
<td>$263.00</td>
</tr>
<tr>
<td>Patrick Moley</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$213.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Alex Kramm</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$295.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$232.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>Eli Abboud</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$191.00</td>
<td>$189.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$210.00</td>
<td>$235.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MarketAxess Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of MarketAxess Holdings compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of MarketAxess Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into MarketAxess Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MKTX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on MarketAxess Holdings analyst ratings.</a>
<h2>Get to Know MarketAxess Holdings Better</h2>
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.
<h3>Understanding the Numbers: MarketAxess Holdings's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: MarketAxess Holdings displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 2.61%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: MarketAxess Holdings's net margin excels beyond industry benchmarks, reaching 32.18%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): MarketAxess Holdings's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 4.69%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): MarketAxess Holdings's ROA excels beyond industry benchmarks, reaching 3.6%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.05, MarketAxess Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MKTX

The Analyst Verdict: MarketAxess Holdings In The Eyes Of 10 Experts

11 analysts have shared their evaluations of Ares Management (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARES#NYSE">ARES</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $170.82, along with a high estimate of $201.00 and a low estimate of $142.00. This current average has decreased by 9.18% from the previous average price target of $188.09. 
<img src="https://www.benzinga.com/files/images/story/2025/1746741643_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Ares Management by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Scharf</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$185.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$156.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$182.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Michael Cyprys</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$152.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Bill Katz</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$161.00</td>
<td>$216.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$156.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>Brian McKenna</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$165.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Benjamin Budish</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$142.00</td>
<td>$217.00</td>
</tr>
<tr>
<td>Craig Siegenthaler</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$201.00</td>
<td>$221.00</td>
</tr>
<tr>
<td>Alexander Blostein</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$166.00</td>
<td>$188.00</td>
</tr>
<tr>
<td>Michael Brown</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$187.00</td>
<td>$215.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Ares Management. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Ares Management compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Ares Management's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ares Management's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ARES/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ares Management analyst ratings.</a>
<h2>Get to Know Ares Management Better</h2>
Ares Management Corp is an asset management company. It offers investors investment-related advice and strategies for capital growth. The company's operating segments include Credit Group, Private Equity Group, Real Assets, Secondaries Group, and Others. Its Credit Group generates maximum revenue and manages credit strategies across the liquid and illiquid spectrum. Private Equity Group manages investment strategies categorized as corporate private equity, infrastructure and power, and special opportunities, Real Estate Group manages comprehensive equity and debt strategies across real estate &amp; infrastructure investments. The Secondaries Group invests in secondary markets across a range of alternative asset class strategies, including private equity, real estate, infrastructure, &amp; credit.
<h3>Unraveling the Financial Story of Ares Management</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Ares Management's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 19.45%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Ares Management's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -3.39%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.05%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Ares Management's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -0.17%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Ares Management's debt-to-equity ratio stands notably higher than the industry average, reaching 6.31. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ARES

Assessing Ares Management: Insights From 11 Financial Analysts

i3 Verticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IIIV#NASDAQ">IIIV</a>) lowers FY2025 Adj EPS guidance from $1.05-$1.25 to $0.96-$1.06 vs $1.17 analyst estimate. Lowers FY2025 sales outlook from $243.00 million-$263.00 million to $207.00 million-$217.00 million vs $250.53 million estimate.

IIIV

i3 Verticals Lowers FY2025 Adj EPS Guidance from $1.05-$1.25 to $0.96-$1.06 vs $1.17 Est; Lowers FY2025 Sales Guidance from $243.00M-$263.00M to $207.00M-$217.00M vs $250.53M Est

In the preceding three months, 5 analysts have released ratings for CDW (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDW#NASDAQ">CDW</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $186.0, a high estimate of $210.00, and a low estimate of $160.00. A decline of 12.35% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1746741636_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of CDW's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asiya Merchant</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$180.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>David Vogt</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$210.00</td>
<td>$236.00</td>
</tr>
<tr>
<td>George Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$205.00</td>
<td>$223.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$222.00</td>
</tr>
<tr>
<td>Asiya Merchant</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$160.00</td>
<td>$220.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to CDW. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CDW compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for CDW's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
To gain a panoramic view of CDW's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CDW/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CDW analyst ratings.</a>
<h2>Get to Know CDW Better</h2>
CDW Corp is a multi-brand provider of information technology ("IT") solutions to small, medium, and large business, government, education, and healthcare customers in the United States, the United Kingdom, and Canada. The company's broad array of offerings ranges from discrete hardware and software products to integrated IT solutions and services that include on-premise and cloud capabilities across hybrid infrastructure, digital experience, and security. The company has five operating segments namely, Corporate, Small Business, Public, CDW UK, and CDW Canada. The Corporate segment generates the majority of its revenue and serves USA private sector business customers.
<h3>CDW's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: CDW displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 3.34%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: CDW's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.09% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): CDW's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 11.24% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.82%, the company showcases effective utilization of assets.
Debt Management: CDW's debt-to-equity ratio stands notably higher than the industry average, reaching 2.55. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CDW Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Looking into the current session, CPI Card Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) shares are trading at $19.85, after a 1.64% decrease. Over the past month, the stock fell by 6.29%, but over the past year, it actually went up by 0.96%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1746741627_0.png" alt="Past Year Chart" />

<h3>Evaluating CPI Card P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
CPI Card has a lower P/E than the aggregate P/E of 25.28 of the Technology Hardware, Storage &amp; Peripherals industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1746741628_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Comments

Vontier

Notizie

Ultime notizie per Vontier (NYSE:VNT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO